Gilead Sciences, Inc. $GILD Shares Sold by IFP Advisors Inc

IFP Advisors Inc cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 48.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,745 shares of the biopharmaceutical company's stock after selling 6,376 shares during the period. IFP Advisors Inc's holdings in Gilead Sciences were worth $748,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Smallwood Wealth Investment Management LLC purchased a new position in shares of Gilead Sciences during the first quarter worth approximately $25,000. Activest Wealth Management grew its position in shares of Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 227 shares during the last quarter. Goodman Advisory Group LLC purchased a new position in shares of Gilead Sciences during the first quarter worth approximately $29,000. Colonial Trust Advisors grew its position in shares of Gilead Sciences by 304.3% during the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 213 shares during the last quarter. Finally, Core Alternative Capital grew its position in shares of Gilead Sciences by 370.8% during the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after acquiring an additional 241 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $111.66, for a total value of $1,116,600.00. Following the sale, the chief executive officer directly owned 591,203 shares in the company, valued at $66,013,726.98. The trade was a 1.66% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $113.57, for a total transaction of $283,925.00. Following the completion of the sale, the chief financial officer owned 159,555 shares in the company, valued at $18,120,661.35. This represents a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 66,000 shares of company stock worth $7,632,100 in the last three months. Corporate insiders own 0.27% of the company's stock.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $118.21 on Tuesday. The firm has a market capitalization of $146.68 billion, a P/E ratio of 23.55, a PEG ratio of 0.80 and a beta of 0.34. Gilead Sciences, Inc. has a one year low of $84.34 and a one year high of $121.83. The company's fifty day moving average is $114.72 and its two-hundred day moving average is $110.30. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.96 by $0.05. The company had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business's revenue was up 1.4% on a year-over-year basis. During the same period in the previous year, the firm earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were given a $0.79 dividend. The ex-dividend date was Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. Gilead Sciences's payout ratio is currently 62.95%.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Dbs Bank upgraded shares of Gilead Sciences to a "moderate buy" rating in a research report on Friday, September 5th. JPMorgan Chase & Co. lifted their price objective on shares of Gilead Sciences from $135.00 to $145.00 and gave the company an "overweight" rating in a research report on Tuesday, September 16th. UBS Group lifted their price objective on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research report on Friday, August 8th. Daiwa Capital Markets upgraded shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price objective on the stock in a research report on Tuesday, August 19th. Finally, Daiwa America upgraded shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $118.08.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.